HuiHe Healthcare completes Series D financing round raising hundreds of millions

HuiHe Healthcare announces completion of Series D financing round. This round was strategically led by Taiping Medical and Health Fund, with continued investment from existing shareholder Sherpa Healthcare Partners. This marks another significant milestone for HuiHe Healthcare since its Series C+ financing round in 2022, demonstrating that HuiHe Healthcare's innovative capabilities in the field of structural heart disease interventional therapy have garnered high recognition from the capital market.

In recent years, insurance capital has become a significant driving force in the development of the medical and healthcare industry. As a typical representative of "patient capital," insurance funds possess unique advantages including long-term orientation, stability, and cross-cycle allocation capabilities. These characteristics align closely with the healthcare industry's own traits of long development cycles and high capital intensity. Furthermore, as a major payer within the healthcare ecosystem, the insurance sector has an inherent synergy with innovative medical device companies. This enables the rational construction of a comprehensive health management ecosystem integrating "clients + payers + demand creators + resource providers," fostering deep collaboration between the core insurance business and the medical industry.

HuiHe Healthcare's ability to attract investment from Taiping Medical and Health Fund under China Taiping stems from its unique competitive advantages and substantial growth potential. The company holds industry-leading positions in delivery systems, precision manufacturing, simulation modeling, and automated production. Within the cardiovascular intervention field, it boasts multiple self-developed, globally leading commercialized products. Its flagship, world-first core product, the K-Clip® Transcatheter Tricuspid Valve Repair System, replicates classical surgical techniques to treat tricuspid regurgitation via a minimally invasive procedure. Approved for market by China's National Medical Products Administration (NMPA) in March 2025, the K-Clip® system has now entered large-scale commercial application.

According to information obtained by VCBeat, the field of structural heart disease presents significant unmet clinical needs. Data from the Chinese Circulation Journal indicates that in 2023, the number of Chinese hospitals admitting inpatients for structural heart disease increased by 32.5% compared to 2022, rising from 5,129 to 6,794 hospitals. Concurrently, the volume of inpatient visits surged by 38.1%, from 3.39 million to 4.68 million patients. The vast gap between the high prevalence and low intervention rates in this area is attracting increasing global attention within the cardiovascular community. HuiHe Healthcare's original, self-developed products offer a breakthrough solution addressing this very gap.